NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

There was no “double dosing” and they did not “blow the comparator” with crossover. Crossover was an ethical requirement of the regulator and the patients as well. It wasn’t an option.

The fact is, you and others seem to want to make the trial a practical impossibility, as I explained early this morning. So your arguments fall apart because that is not how regulation works and definitely not in a case like this one, where patients and doctors want the treatment, the results are shown with significance and there is no safety issue and there are very few to no side-effects. You have what is clearly extension of survival, after all other treatments have ended, and in the case of recurrence and with MGMT patients. You have also what looks like, in the many instances where patients had swelling, and then the tumor disappeared, a variety of ways in which results validate the method of action. I would bet they have biomarkers that show it too, which they likely will have available for the regulator.

I just continue to see you throwing out made-up “facts” and false notions that could not possibly justify your conclusions in the end. It’s just my opinion. But you continue to have nothing but a good imagination on key details to validate your argument.